AbbVie Inc. Completes Acquisition of Apogee Therapeutics

What Happened

• AbbVie Inc. announced on September 3, 2026 that it has completed its acquisition of Apogee Therapeutics, Inc. The company issued a press release announcing the closing, which is attached to the Form 8-K as Exhibit 99.1 and was furnished under Item 7.01 (Regulation FD Disclosure).

Key Details

• Transaction announced as closed: AbbVie completed acquisition of Apogee Therapeutics, Inc. (press release dated Sept 3, 2026).
• Filing: Form 8-K filed Sept 3, 2026 discloses the press release under Item 7.01 and includes Exhibit 99.1 (press release) and Exhibit 104 (Inline XBRL cover page).
• The press release is incorporated by reference into the 8-K (Exhibit 99.1).

Why It Matters

• Completion of the Apogee acquisition is a material corporate development for AbbVie; it may affect the company’s pipeline, future product offerings, and financial results.
• Investors should read the attached press release for transaction details and monitor future SEC filings (e.g., subsequent 8-Ks, 10-Qs) for information on purchase price allocation, integration plans, and the acquisition’s financial impact.